Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338619 | 0.83 | HTR7 (0.62) | AKT2CHEK1HTR7TAAR1IKBKB | |
| SCHEMBL3338676 | 0.83 | CHEK1 (0.51) | AKT2CHEK1HTR7TAAR1IKBKB | |
| SCHEMBL3341674 | 0.81 | CHEK1 (0.49) | AKT2CHEK1HTR7IKBKBIKBKE | |
| SCHEMBL3340562 | 0.80 | DRD2 (0.49) | AKT2CHEK1HTR7DRD2DRD1 | |
| SCHEMBL1977037 | 0.76 | AKT2 (0.54) | AKT2CHEK1IKBKBIKBKEKMT2A | |
| SCHEMBL13035810 | 0.76 | AKT2 (0.67) | AKT2CHEK1IKBKBIKBKEKMT2A | |
| SCHEMBL24514606 | 0.74 | AKT2 (0.59) | AKT2CHEK1TAAR1IKBKBIKBKE | |
| SCHEMBL5217255 | 0.73 | BRD4 (0.55) | HTR7TAAR1 | |
| SCHEMBL1048316 | 0.73 | HTR7 (0.61) | HTR7TAAR1KARS1DRD2DRD1 | |
| SCHEMBL30829475 | 0.73 | AKT2 (0.62) | AKT2CHEK1IKBKBIKBKEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | claimed |
| CN-101616897-A | The ethylamino-phenyl derivatives that heterocyclic radical replaces, its preparation and as the purposes of medicament | ESTEVE LABOR DR | 2009-12-30 | — | — | CN | claimed |
| EP-2114894-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-11 | — | — | EP | claimed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | claimed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE,S.A. (ES) | 2010-06-17 | — | — | US | disclosed |
| CN-101616897-A | The ethylamino-phenyl derivatives that heterocyclic radical replaces, its preparation and as the purposes of medicament | ESTEVE LABOR DR | 2009-12-30 | — | — | CN | disclosed |
| EP-2114894-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152252-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | PKM, PKLR, HNMT | AKT2 3617/4885CHEK1 2634/4885HTR7 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.